Inventor · disambiguated record
Shrikant Deshpande
Also filed as: DESHPANDE SHRIKANT · DESHPANDE SHRIKANT L
15 granted patents·10 pending applications·174 citations·filing 1998–2024
91Inventor score
Files withBRISTOL MYERS SQUIBB CO10CORIXA CORP3GEN ELECTRIC3DESHPANDE SHRIKANT2DESHPANDE SHRIKANT L1
Top patents by PatentIndex Score
25 records- 0192US8258266B2IP-10 antibodies and their usesDESHPANDE SHRIKANT·Filed 2009·Granted Sep 4, 2012·28 cites·17 claims
- 0292US7152157B2System and method for dynamic resource configuration using a dependency graphSUN MICROSYSTEMS INC·Filed 2003·Granted Dec 19, 2006·118 cites·21 claims
- 0390US12077584B2Methods of treating HLA-E-expressing cancers by administering antibodies which bind human natural killer cell inhibitory receptor group 2A (NKG2A)BRISTOL MYERS SQUIBB CO·Filed 2022·Granted Sep 3, 2024·1 cites·76 claims
- 0488US11274150B2Anti-human natural killer cell inhibitory receptor group 2A protein (NKG2A) antibodiesBRISTOL MYERS SQUIBB CO·Filed 2019·Granted Mar 15, 2022·2 cites·113 claims
- 0586US12441799B2Activatable anti-CTLA-4 antibodies and uses thereofBRISTOL MYERS SQUIBB CO·Filed 2021·Granted Oct 14, 2025·1 cites·14 claims
- 0683US2025101100A1Anti-nkg2a antibodies and uses thereofBRISTOL MYERS SQUIBB CO·Filed 2024·Application pending·0 cites
- 0780US11117968B2Activatable anti-CTLA-4 antibodies and uses thereofBRISTOL MYERS SQUIBB CO·Filed 2017·Granted Sep 14, 2021·2 cites·20 claims
- 0878US11981734B2Nucleic acid molecules encoding antibodies which bind natural killer cell inhibitory receptor group 2A protein (NKG2A)BRISTOL MYERS SQUIBB CO·Filed 2022·Granted May 14, 2024·0 cites·163 claims
- 0976US11708405B2IP-10 antibodies and their usesBRISTOL MYERS SQUIBB CO·Filed 2019·Granted Jul 25, 2023·1 cites·21 claims
- 1075US10556948B2IP-10 antibodies and their usesBRISTOL MYERS SQUIBB CO·Filed 2016·Granted Feb 11, 2020·2 cites·19 claims
- 1175US7702600B2Systems and methods for clinical decision crawler agentGEN ELECTRIC·Filed 2006·Granted Apr 20, 2010·6 cites·12 claims
- 1274US8945546B2IP-10 antibodies and their usesDESHPANDE SHRIKANT·Filed 2012·Granted Feb 3, 2015·2 cites·21 claims
- 1373US9994633B2IP-10 antibodies and their usesSQUIBB & SONS LLC·Filed 2014·Granted Jun 12, 2018·1 cites·4 claims
- 1457US2005191293A1IP-10 antibodies and their usesFiled 2004·Application pending·0 cites
- 1555US10676773B2Antibodies conjugatable by transglutaminase and conjugates made therefromBRISTOL MYERS SQUIBB CO·Filed 2016·Granted Jun 9, 2020·0 cites·6 claims
- 1655US2009125555A1Method and apparatus for flexible archivingGEN ELECTRIC·Filed 2007·Application pending·0 cites
- 1753US2010153361A1Systems and methods for clinical decision crawler agentDESHPANDE SHRIKANT L·Filed 2010·Application pending·0 cites
- 1852US6171590B1Chemokine receptor peptide for inducing an immune responseCORIXA CORP·Filed 1998·Granted Jan 9, 2001·10 cites·42 claims
- 1951US12110337B2Anti-CD27 antibodies and uses thereofBRISTOL MYERS SQUIBB CO·Filed 2019·Granted Oct 8, 2024·0 cites·25 claims
- 2049US2006251975A1System and method for retrieving radiographic imagesGEN ELECTRIC·Filed 2005·Application pending·0 cites
- 2144US2003144477A1Immunodominant acetylcholine receptor alpha subunit peptide: MHC complexesCORIXA CORP·Filed 2002·Application pending·0 cites
- 2241US2003103993A1HLA-DR2 binding peptidesCORIXA CORP·Filed 2001·Application pending·0 cites
- 2341US2002039578A1Methods for treating disease with antibodies to CXCR3Filed 2001·Application pending·0 cites
- 2441US2001006942A1Chemokine receptor peptide vaccines for treatment and prevention of diabetesFiled 2001·Application pending·0 cites
- 2532US2005048066A1Identification of potential immunodominant acetylcholine receptor alpha subunitFiled 2001·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →